Based on the Catalent Inc stock forecast from 4 analysts, the average analyst target price for Catalent Inc is USD 63.38 over the next 12 months. Catalent Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Catalent Inc is Bearish, which is based on 3 positive signals and 9 negative signals. At the last closing, Catalent Inc’s stock price was USD 59.10. Catalent Inc’s stock price has changed by -0.52% over the past week, -1.65% over the past month and +48.23% over the last year.
No recent analyst target price found for Catalent Inc
No recent average analyst rating found for Catalent Inc
Company Overview Catalent Inc
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey. Read Less
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment p...Read More
Frequently Asked Questions About Catalent Inc (CTLT) Stock
Based on ratings from 4 analysts Catalent Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on CTLT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for CTLT is USD 63.38 over the next 12 months. The maximum analyst target price is USD 63.5 while the minimum anlayst target price is USD 63.
CTLT stock's Price/Earning ratio is 211.02.
Our analysis grades CTLT stock's Price / Earning ratio at F. This means that CTLT stock's Price/Earning ratio is above 89% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this CTLT may be a overvalued for its sector.
The last closing price of CTLT's stock was USD 59.10.
The most recent market capitalization for CTLT is USD 10.78B.
Based on targets from 4 analysts, the average taret price for CTLT is projected at USD 63.38 over the next 12 months.
This means that CTLT's stock price may go up by +7.23% over the next 12 months.
We can't find any ETFs which contains Catalent Inc's stock.
As per our most recent records Catalent Inc has 17,000 Employees.
Catalent Inc's registered address is 14 Schoolhouse Road, Somerset, NJ, United States, 08873.
You can get more information about it from Catalent Inc's website at https://www.catalent.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Catalent Inc (CTLT) Stock
Based on ratings from 4 analysts Catalent Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on CTLT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for CTLT is USD 63.38 over the next 12 months. The maximum analyst target price is USD 63.5 while the minimum anlayst target price is USD 63.
CTLT stock's Price/Earning ratio is 211.02.
Our analysis grades CTLT stock's Price / Earning ratio at F. This means that CTLT stock's Price/Earning ratio is above 89% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this CTLT may be a overvalued for its sector.
The last closing price of CTLT's stock was USD 59.10.
The most recent market capitalization for CTLT is USD 10.78B.
Based on targets from 4 analysts, the average taret price for CTLT is projected at USD 63.38 over the next 12 months.
This means that CTLT's stock price may go up by +7.23% over the next 12 months.
We can't find any ETFs which contains Catalent Inc's stock.
As per our most recent records Catalent Inc has 17,000 Employees.
Catalent Inc's registered address is 14 Schoolhouse Road, Somerset, NJ, United States, 08873.
You can get more information about it from Catalent Inc's website at https://www.catalent.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CTLT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
